Russell Investments Group
SUPN icon

Russell Investments Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Russell Investments Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.99M Buy
85,767
+27,991
+48% +$1.34M ﹤0.01% 1661
2026
Q1 		$2.99M Sell
57,776
-30,294
-34% -$1.54M ﹤0.01% 1643
2025
Q4 		$4.38M Buy
88,070
+25,573
+41% +$1.24M ﹤0.01% 1412
2025
Q3 		$2.98M Buy
62,497
+6,669
+12% +$269K ﹤0.01% 1634
2025
Q2 		$1.76M Sell
55,828
-19,202
-26% -$615K ﹤0.01% 1785
2025
Q1 		$2.46M Sell
75,030
-21,365
-22% -$757K ﹤0.01% 1570
2024
Q4 		$3.49M Sell
96,395
-13,152
-12% -$463K ﹤0.01% 1359
2024
Q3 		$3.42M Buy
109,547
+9,285
+9% +$290K ﹤0.01% 1392
2024
Q2 		$2.68M Buy
100,262
+2,274
+2% +$65.9K ﹤0.01% 1488
2024
Q1 		$3.34M Buy
97,988
+65,880
+205% +$1.96M 0.01% 1358
2023
Q4 		$929K Buy
32,108
+2,212
+7% +$58.6K ﹤0.01% 2000
2023
Q3 		$824K Sell
29,896
-20,565
-41% -$626K ﹤0.01% 2021
2023
Q2 		$1.52M Buy
50,461
+42
+0.1% +$1.47K ﹤0.01% 1716
2023
Q1 		$1.83M Buy
50,419
+15,089
+43% +$580K ﹤0.01% 1641
2022
Q4 		$1.26M Hold
35,330
– – ﹤0.01% 1856
2022
Q3 		$1.2M Buy
35,330
+20,590
+140% +$670K ﹤0.01% 1846
2022
Q2 		$426K Hold
14,740
– – ﹤0.01% 2323
2022
Q1 		$476K Sell
14,740
-9,587
-39% -$294K ﹤0.01% 2240
2021
Q4 		$708K Buy
24,327
+9,587
+65% +$291K ﹤0.01% 2318
2021
Q3 		$393K Sell
14,740
-4,286
-23% -$115K ﹤0.01% 2562
2021
Q2 		$584K Sell
19,026
-56,675
-75% -$1.74M ﹤0.01% 2530
2021
Q1 		$1.98M Sell
75,701
-38,622
-34% -$1.08M ﹤0.01% 1880
2020
Q4 		$2.88M Sell
114,323
-66,941
-37% -$1.44M 0.01% 1558
2020
Q3 		$3.78M Sell
181,264
-107,782
-37% -$2.45M 0.01% 1304
2020
Q2 		$6.81M Buy
289,046
+160,345
+125% +$3.54M 0.02% 924
2020
Q1 		$2.23M Buy
128,701
+24,819
+24% +$522K 0.01% 1410
2019
Q4 		$2.42M Sell
103,882
-78,828
-43% -$1.91M ﹤0.01% 1625
2019
Q3 		$5.02M Sell
182,710
-37,588
-17% -$1.11M 0.01% 1199
2019
Q2 		$7.06M Sell
220,298
-18,449
-8% -$632K 0.01% 1060
2019
Q1 		$8.19M Sell
238,747
-116,560
-33% -$4.34M 0.02% 991
2018
Q4 		$11.6M Sell
355,307
-33,166
-9% -$1.43M 0.03% 736
2018
Q3 		$19.5M Sell
388,473
-43,551
-10% -$2.15M 0.04% 583
2018
Q2 		$25.5M Sell
432,024
-512,362
-54% -$26.5M 0.05% 430
2018
Q1 		$43.3M Buy
944,386
+53,026
+6% +$2.21M 0.07% 323
2017
Q4 		$36.4M Buy
891,360
+55,020
+7% +$2.17M 0.06% 374
2017
Q3 		$33.5M Sell
836,340
-184,420
-18% -$7.98M 0.06% 401
2017
Q2 		$44M Buy
1,020,760
+144,720
+17% +$5.15M 0.08% 313
2017
Q1 		$27.4M Buy
876,040
+17,180
+2% +$460K 0.05% 447
2016
Q4 		$21.8M Buy
+858,860
New +$19.2M 0.04% 522

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Russell Investments Group's SUPN Position: Q2 2026 in Review

Russell Investments Group increased its Supernus Pharmaceuticals (SUPN) stake by 48% in Q2 2026, buying an estimated $1.34M and bringing the position to 85,767 shares worth $3.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1661.

Russell Investments Group first reported a position in SUPN in Q4 2016 and has held it in 39 quarters since. The position peaked at $44M in Q2 2017. 139 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Russell Investments Group held 85,767 shares of Supernus Pharmaceuticals worth $3.99M as of Q2 2026.
  • Russell Investments Group bought 27,991 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.34M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1661 holding.
  • Russell Investments Group first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
  • Russell Investments Group's Supernus Pharmaceuticals position peaked at $44M in Q2 2017.
  • 139 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.